BofA cuts McKesson stock price target on GLP-1 headwinds By Investing.com

BofA cut its McKesson price target to $1,000 from $1,040 while keeping a Buy; shares trade at $884 and analyst targets cited in the article range from $860 to $1,107. BofA flagged that falling cash-pay GLP-1 prices (Wegovy/Zepbound) could shift prescriptions away from insurance, estimating insurance-eligible GLP-1 prescriptions could be -10% to +10% in fiscal 2027 and that McKesson's take rate per script could be flat-to-down, which may pressure Prescription Technology Solutions EBIT in FY27. Management change: CFO Britt Vitalone will retire and be succeeded by Kenny Cheung on May 29, 2026; several brokers (Argus $1,050, Leerink $1,085, Evercore $1,000) maintained or raised targets and 12 analysts have recently revised earnings higher.

Analysis

The immediate structural shock is not a single product but a pricing paradigm shift: cash-pay GLP-1s have established an outside-in price benchmark that is compressing the insurer-mediated economics of prescription flows. That pressure lowers per-script take-rates, but also changes customer bargaining power — retail pharmacies and PBMs can lean on cash-list prices to renegotiate reimbursement schedules, creating a sustained margin headwind for distributors unless offset by volume, new services, or price resets.

McKesson’s near-term earnings sensitivity is concentrated in its Prescription Technology and distribution economics, while the longer-term optionality lives in the Medical‑Surgical separation and reinvestment into higher-growth adjacencies. Execution risk on separation and the CFO handoff is a multi-quarter operational and communications test: mis-timed working-capital moves or an opaque carve-out could widen the valuation gap even if core fundamentals stabilize.

Key catalysts to watch on 0–24 month horizons: weekly script trends for GLP-1s (directional signal in 4–12 weeks), any insurer formulary reversals or coverage expansions (month-to-quarters), and discrete separation milestones (expected over the next 12–24 months) that can unlock multiple re-rating paths. Tail risks that would reverse the constructive case are a sustained deflationary spiral in cash prices or regulatory interventions that force broader insurer coverage without compensating reimbursement — both would materially compress distributor take-rates for several quarters.

Key Decisions for Investors

• Tactical long (MCK) — Initiate a 2–3% portfolio weight on a 5–8% pullback from current levels; hold 12–24 months to capture separation execution and re‑rating. Risk: concentrated exposure to GLP-1 take‑rate compression and execution missteps; Reward: asymmetric upside if management proves ability to offset lost prescription economics via higher-margin services or successful carve‑out.
• Options overlay (MCK) — Buy a 12–18 month call debit spread roughly 15–25% OTM to express a constructive multi-quarter view while capping premium outlay; fund by selling a near-term (3–6 month) covered call against part of the position to harvest time decay. Risk: limited to net premium paid; Reward: 3:1+ upside if separation triggers re‑rating and EPS trajectory recovers.
• Downside protection (MCK) — Purchase a 6–9 month put spread 10–15% OTM sized to limit portfolio drawdown to <2% of NAV if macro or GLP‑1 deflation accelerates; prefer a vertical to keep hedging cost predictable. Risk: cost of hedge reduces short-term carry; Reward: protects capital against a policy- or price-driven adverse shock that could shave multiple quarters of EPS.
• Rotate from momentum names into stable cash flows — Reallocate up to 50% of any existing positions in volatile growth names (e.g., SMCI/APP) into MCK on strength in GLP-1 headlines that create headline-driven weakness in distributors. Timeframe 6–12 months; Risk: opportunity cost if momentum names rerate higher; Reward: shifts exposure to a balance-sheet-rich, cash-generative business with idiosyncratic catalysts (separation/CFO transition).